<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_WLC-Milwaukee skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:WLC-Milwaukee</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV style="padding-left:10%;padding-right:18%;font-size:11pt"><CENTER><DIV id="slideshow"><DIV class="textboxes" id="main_view"><DIV class="paging"><A href="#" rel="1">1</A><A href="#" rel="2">2</A><A href="#" rel="3">3</A><A href="#" rel="4">4</A><A href="#" rel="5">5</A><A href="#" rel="6">6</A><A href="#" rel="7">7</A></DIV><DIV class="pause"><A href="#">II</A></DIV></DIV></DIV></CENTER></DIV><DIV class="highlightBox" style="padding-right:18%;padding-left:18%;"><TITLE>Slide Show</TITLE><CENTER><H1 id="heading_1"><FONT color="#610B0B"><B>Project Description</B></FONT></H1></CENTER><P>The WLC-Milwaukee team is looking into phage therapy for this year's project. We are looking for phages specific to the outer-membrane efflux pore protein TolC. TolC analogs are found in most gram-negative bacteria, and they have been implicated as an essential protein in an efflux-based resistance mechanism to certain types of antibiotics. Our project involves expressing TolC homologs from infectious strains of bacteria in a <I>tolC</I> knockout strain of <I>Escherichia coli</I>. We are using these transgenic <I>E. coli</I> to search for bacteriophages specific to our selected gastrointestinal tract pathogen's versions of TolC. Our hope is that the phages specific for a pathogen's TolC protein can be used in combination with antibiotic therapy. This will place antibiotic resistant bacteria in a lose-lose situation: the bacteria which try to efflux the antibiotics via TolC will expose themselves to the pathogen's TolC-specific phage, while those which do not express TolC will be weakened to the antibiotic therapy.  </P><CENTER><FONT size="4" color="#610B0B"><I>To Learn More, Click the Links Below</I></FONT></CENTER></DIV></DIV><DIV id="wlcHeader" class="navLinks" style="left:0px;height:90px;width:100%;"><TABLE width="100%" align="center" cellspacing="0"><TBODY><TR height="90px"><TD id="HomeBox"><A id="homeLink" href="https://2015.igem.org/Team:WLC-Milwaukee" style="text-decoration:none">Home</A></TD><TD id="ProjectBox"><A id="projectLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Project" style="text-decoration:none">Project</A></TD><TD id="PartsBox"><A id="partsLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Parts" style="text-decoration:none">Parts</A></TD><TD id="NotebookBox"><A id="notebookLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Notebook" style="text-decoration:none">Documentation</A></TD><TD id="ModelingBox"><A id="modelingLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Modeling" style="text-decoration:none">Modeling</A></TD><TD id="practBox"><A id="practLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Practices">Policy</A></TD><TD id="teamBox"><A id="teamLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Attributions">People</A></TD></TR></TBODY></TABLE></DIV></DIV></DIV></DIV></BODY></HTML>